- Home
- CRDL vs FCEL Comparison
CRDL vs FCEL Comparison
Compare CRDL & FCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- FCEL
- Stock Information
- Founded
- CRDL 2017
- FCEL 1969
- Country
- CRDL Canada
- FCEL United States
- Employees
- CRDL N/A
- FCEL N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- FCEL Industrial Machinery/Components
- Sector
- CRDL Health Care
- FCEL Energy
- Exchange
- CRDL Nasdaq
- FCEL Nasdaq
- Market Cap
- CRDL 102.0M
- FCEL 96.7M
- IPO Year
- CRDL N/A
- FCEL 1992
- Fundamental
- Price
- CRDL $1.03
- FCEL $3.90
- Analyst Decision
- CRDL Strong Buy
- FCEL Hold
- Analyst Count
- CRDL 3
- FCEL 6
- Target Price
- CRDL $9.00
- FCEL $14.28
- AVG Volume (30 Days)
- CRDL 226.1K
- FCEL 606.8K
- Earning Date
- CRDL 05-13-2025
- FCEL 06-09-2025
- Dividend Yield
- CRDL N/A
- FCEL N/A
- EPS Growth
- CRDL N/A
- FCEL N/A
- EPS
- CRDL N/A
- FCEL N/A
- Revenue
- CRDL N/A
- FCEL $114,438,000.00
- Revenue This Year
- CRDL N/A
- FCEL $42.70
- Revenue Next Year
- CRDL N/A
- FCEL $13.23
- P/E Ratio
- CRDL N/A
- FCEL N/A
- Revenue Growth
- CRDL N/A
- FCEL 11.09
- 52 Week Low
- CRDL $0.77
- FCEL $3.71
- 52 Week High
- CRDL $3.12
- FCEL $30.90
- Technical
- Relative Strength Index (RSI)
- CRDL 50.17
- FCEL 27.28
- Support Level
- CRDL $0.92
- FCEL $3.72
- Resistance Level
- CRDL $1.08
- FCEL $4.04
- Average True Range (ATR)
- CRDL 0.11
- FCEL 0.34
- MACD
- CRDL 0.02
- FCEL 0.04
- Stochastic Oscillator
- CRDL 72.64
- FCEL 1.75
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About FCEL FuelCell Energy Inc.
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products and electrolysis platforms that decarbonize power and produce hydrogen. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company operates in USA, South Korea, Europe and Canada. Majority of revenue is from USA and South Korea.